Wall Street brokerages predict that Galapagos NV (NASDAQ:GLPG) will report ($0.68) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Galapagos NV’s earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($0.91). Galapagos NV posted earnings per share of ($0.11) in the same quarter last year, which suggests a negative year over year growth rate of 518.2%. The firm is scheduled to report its next earnings results on Friday, August 4th.
On average, analysts expect that Galapagos NV will report full year earnings of ($2.26) per share for the current fiscal year, with EPS estimates ranging from ($3.29) to ($1.47). For the next year, analysts anticipate that the firm will post earnings of ($1.33) per share, with EPS estimates ranging from ($3.92) to $0.10. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Galapagos NV.
GLPG has been the subject of a number of analyst reports. Janney Montgomery Scott downgraded shares of Galapagos NV from a “buy” rating to a “sell” rating in a research report on Monday, April 24th. Zacks Investment Research downgraded shares of Galapagos NV from a “buy” rating to a “hold” rating in a research report on Tuesday, March 21st. Nomura cut their price objective on shares of Galapagos NV from $108.00 to $121.00 and set a “buy” rating for the company in a research report on Thursday, June 22nd. Stifel Nicolaus upped their price objective on shares of Galapagos NV from $65.00 to $83.00 and gave the stock a “hold” rating in a research report on Monday, May 1st. Finally, Instinet restated a “buy” rating and set a $108.00 price objective (down previously from $121.00) on shares of Galapagos NV in a research report on Thursday, June 22nd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Galapagos NV currently has a consensus rating of “Buy” and a consensus price target of $94.00.
Several institutional investors have recently made changes to their positions in GLPG. Tower Research Capital LLC TRC bought a new position in shares of Galapagos NV during the first quarter worth about $161,000. Bank of Montreal Can increased its position in shares of Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock worth $168,000 after buying an additional 1,922 shares in the last quarter. Cim Investment Mangement Inc. bought a new position in shares of Galapagos NV during the first quarter worth about $203,000. Karp Capital Management Corp bought a new position in shares of Galapagos NV during the first quarter worth about $206,000. Finally, Airain ltd bought a new position in shares of Galapagos NV during the first quarter worth about $237,000. Institutional investors and hedge funds own 19.92% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by WKRB News and is owned by of WKRB News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.wkrb13.com/markets/2286286/analysts-anticipate-galapagos-nv-glpg-to-announce-0-68-earnings-per-share.html.
Galapagos NV (NASDAQ GLPG) traded down 0.95% on Wednesday, reaching $75.96. 161,354 shares of the company’s stock were exchanged. Galapagos NV has a 1-year low of $51.91 and a 1-year high of $94.88. The stock has a market cap of $3.51 billion, a PE ratio of 723.43 and a beta of 1.78.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286286/analysts-anticipate-galapagos-nv-glpg-to-announce-0-68-earnings-per-share.html
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.